Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781806 · ClinicalTrials.gov registry record · Phase 4
A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 328
- Enrollment target
NCT01781806 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 328 participants.
The verdict
NCT01781806, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 328 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, acceptability and feasibility of delivery of Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis) PEP as part of combination HIV prevention services for high-risk MSM and transgender women.
Interventions
- DRUG emtricitabine 200mg/tenofovir 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781806
The ClinicalTrials.gov registry entry for NCT01781806 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which emtricitabine 200mg/tenofovir 300mg is the first listed.
NCT01781806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01781806 about?
NCT01781806 is a clinical study titled "A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services". The purpose of this study is to evaluate the safety, acceptability and feasibility of delivery of Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis) PEP as part of combination HIV prevention services for high-risk MSM and transgender women.
What is the current status of trial NCT01781806?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 328 participants. The study started on 2013-05. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01781806?
The interventions under investigation include: emtricitabine 200mg/tenofovir 300mg (DRUG).
Who is sponsoring clinical trial NCT01781806?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.